Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved in focal adhesion and extracellular matrix (ECM) remodeling. These two processes remodel the tumor cell environment in melanoma through the RAF/MEK cell signaling pathway. However, the combined use of FAK inhibitors with a RAF-MEK clamp overcame this resistance. Read More
Although radiotherapy is widely used in cancer treatment, its effects on the tumor microenvironment (TME) can be immunosuppressive as well as immunostimulatory. Fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in several tumors, with higher levels linked to a weakened immune response to immune checkpoint blockade in patients. Read More
Laekna Inc. has obtained FDA clearance of its IND application for LAE-120, an allosteric and highly potent USP1 inhibitor, for the treatment of advanced solid tumors. Read More
Tyrosine kinase 2 (TYK2), expressed in astrocytes and microglia, is involved in the activation of pathways triggered by proinflammatory cytokines, such as IL-23, IL-12 and type I interferons (IFNs), within the central nervous system (CNS). Dysregulated activation of astrocytes and microglia may contribute to the neuroinflammation associated with progressive forms of multiple sclerosis (MS). Read More
Celldex Therapeutics Inc. has presented preclinical data on their bispecific antibody CDX-622 for the potential treatment of inflammatory disorders. Read More
Shenzhen Salubris Pharmaceuticals Co. Ltd. has disclosed relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of angina pectoris, acute kidney injury, chronic kidney disease, coronary heart disease, heart failure, hypertension and myocardial infarction. Read More
In8bio Inc. has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient numbers of γδ T cell effector cells to deliver clinical impact. The platform could have applications across oncology as well as autoimmune diseases. Read More
The nuclear protein charged amino acid-rich leucine zipper 1 (Crlz-1) has been shown to play a role in the rapid proliferative stages of B-cell development, being targeted by the canonical Wnt/β-catenin signaling pathway.
Virginia Commonwealth University has synthesized nitrogen-walk derivatives of NAN acting as µ-opioid receptor modulators reported to be useful for the treatment of pain, opioid dependency and neurological disorders. Read More
Raythera Inc. has identified TNF-α modulators reported to be useful for the treatment of inflammatory disorders, autoimmune disease, neurological disorders, pain, cardiovascular disorders, cancer, metabolic disorders and eye disorders. Read More
Triple-negative breast cancer (TNBC) remains one of the most aggressive and challenging subtypes to treat due to the lack of targeted therapies. Therefore, identifying molecular drivers of TNBC progression and metastasis is crucial for the development of new treatment strategies. Read More
Xenon Pharmaceuticals Inc. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of pain, anhedonia, depression and seizure disorders. Read More
Jnana Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental disorders and autism spectrum disorders, among others. Read More
Antimicrobial resistance (AMR) is predicted to cause 10 million deaths every year by 2050. Since its identification more than 50 years ago, pleuromutilin has served as a scaffold for the development of new types of antibiotics. Read More
